The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2021 Jun 9

PMID 34104651

Citations 4

Authors

Chuanying Geng

Guangzhong Yang

Huijuan Wang

Zhiyao Zhang

Huixing Zhou

Wenming Chen

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the prognostic role of prothrombin time (PT) and activated partial thromboplastin time (APTT) for newly diagnosed multiple myeloma (MM).

Methods: We retrospectively analyzed 354 patients with newly diagnosed MM who received primary treatment in our center. The propensity score matching technique was used to reduce the bias between groups.

Results: Among 354 patients, lengthened PT or APTT was observed in 154 (43.5%) patients and 200 (56.5%) patients had normal PT and APTT. Patients with lengthened PT or APTT had significantly shorter median overall survival (OS) (37.5 vs. 73.8 months, < 0.001) and progression-free survival (PFS) (23.1 vs. 31.6 months, = 0.001) than those with normal PT and APTT. Univariate Cox proportional hazards regression analyses showed that lengthened PT or APTT was associated with shorter OS (HR = 2.100, 95% CI: 1.525-2.893, < 0.001). Lengthened PT or APTT was also a poor prognostic factor for OS (HR = 3.183, 95% CI: 1.803-5.617, < 0.001) in multivariable analyses. The poor effect of lengthened PT or APTT on PFS was confirmed in univariate analysis (HR = 1.715, 95% CI: 1.244-2.365, = 0.001), but it had no impact on PFS in multivariate analysis ( = 0.197). In the propensity score matching analysis, 154 patients, 77 in each group, were identified. Among 154 matched patients, the OS of patients with lengthened PT or APTT was shorter (38.4 vs. 51.0 months, = 0.030), but PFS was similar (29.0 vs. 35.0 months, = 0.248).

Conclusion: These results demonstrated that lengthened PT or APTT was an independent poor prognostic factor for patients with newly diagnosed MM.

Citing Articles

Effectiveness of D-dimer in predicting distant metastasis in colorectal cancer.

Zhang X, Li W, Wang X, Lin J, Dang C, Diao D PLoS One. 2024; 19(7):e0306909.

PMID: 38995895 PMC: 11244829. DOI: 10.1371/journal.pone.0306909.

Association between PT, PT-INR, and in-hospital mortality in critically ill patients with tumors: A retrospective cohort study.

Liang J, Qin Z, Yang J, Zhao C, He Q, Shang K Front Public Health. 2023; 11:1036463.

PMID: 37026132 PMC: 10070679. DOI: 10.3389/fpubh.2023.1036463.

Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer.

Wang X, Guo Z, Wu X, Chen D, Wang F, Yang L Immunotargets Ther. 2023; 12:1-16.

PMID: 36632330 PMC: 9828302. DOI: 10.2147/ITT.S373866.

Monoclonal gammopathy of undetermined significance (MGUS) characterized by refractory lower gastrointestinal postoperative bleeding with coagulopathy.

Zhang S, Chen Z, Huang M, Zhan R, Wu L, Zhang Q Intractable Rare Dis Res. 2022; 11(4):206-210.

PMID: 36457584 PMC: 9709621. DOI: 10.5582/irdr.2022.01120.

References

Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A . Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol. 2017; 99(5):409-414. DOI: 10.1111/ejh.12923. View

Cheng Q, Cai L, Zhang Y, Chen L, Hu Y, Sun C . Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models. Front Oncol. 2021; 11:639528. PMC: 7973368. DOI: 10.3389/fonc.2021.639528. View

Pandey S, Post S, Alapat D, Smock K, Post G . Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia. Int J Lab Hematol. 2012; 35(4):421-7. DOI: 10.1111/ijlh.12036. View

Rajkumar S, Dimopoulos M, Palumbo A, Blade J, Merlini G, Mateos M . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48. DOI: 10.1016/S1470-2045(14)70442-5. View

Elice F, Fink L, Tricot G, Barlogie B, Zangari M . Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006; 134(4):399-405. DOI: 10.1111/j.1365-2141.2006.06208.x. View

Crowley M, Crowely M, Quinn S, Coleman E, Eustace J, Gilligan O . Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma. J Thromb Thrombolysis. 2014; 39(2):245-9. DOI: 10.1007/s11239-014-1140-z. View

NILEHN J, Nilsson I . Coagulation studies in different types of myeloma. Acta Med Scand Suppl. 1966; 445:194-9. DOI: 10.1111/j.0954-6820.1966.tb02360.x. View

Szudy-Szczyrek A, Mlak R, Mielnik M, Szczyrek M, Nowaczynska A, Homa-Mlak I . Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen. Ann Hematol. 2020; 99(12):2881-2891. PMC: 7683474. DOI: 10.1007/s00277-020-04092-5. View

Huang H, Li H, Li D . Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma. Blood Coagul Fibrinolysis. 2015; 26(5):555-9. DOI: 10.1097/MBC.0000000000000296. View

10.

Teng H, Chen P, Yang Y, Gau J . The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma. Jpn J Clin Oncol. 2007; 37(8):609-14. DOI: 10.1093/jjco/hym074. View

11.

Shen J, Du X, Zhao L, Luo H, Xu Z . Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue. Oncol Lett. 2018; 15(6):10017-10025. PMC: 6004680. DOI: 10.3892/ol.2018.8559. View

12.

Palumbo A, Anderson K . Multiple myeloma. N Engl J Med. 2011; 364(11):1046-60. DOI: 10.1056/NEJMra1011442. View

13.

Kyle R, Gertz M, Witzig T, Lust J, Lacy M, Dispenzieri A . Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78(1):21-33. DOI: 10.4065/78.1.21. View

14.

Soong B, Miller S . Coagulation disorders in cancer. II. Multiple myeloma. Cancer. 1969; 23(6):1388-98. DOI: 10.1002/1097-0142(196906)23:6<1388::aid-cncr2820230621>3.0.co;2-g. View

15.

Coppola A, Tufano A, Di Capua M, Franchini M . Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost. 2011; 37(8):929-45. DOI: 10.1055/s-0031-1297372. View

16.

Chen J, Liu H, Li L, Liu Z, Song J, Wang G . Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function. J Clin Lab Anal. 2019; 33(5):e22888. PMC: 6595344. DOI: 10.1002/jcla.22888. View

17.

Napolitano M, Saccullo G, Bono R, Branca A, Cangialosi C, Mancuso S . Absolute lymphocyte count is unrelated to overall survival in newly diagnosed elderly patients with multiple myeloma treated with immunomodulatory drugs. Leuk Lymphoma. 2014; 56(5):1507-9. DOI: 10.3109/10428194.2014.955021. View

18.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

19.

Gu Y, Jin Y, Ding J, Yujie W, Shi Q, Qu X . Low absolute CD4 T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma. Leuk Lymphoma. 2020; 61(8):1869-1876. DOI: 10.1080/10428194.2020.1751840. View

20.

Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A . Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia. 2014; 28(10):2075-9. DOI: 10.1038/leu.2014.110. View